Eventually, the same research group described an increased production of IL-4 and IL-17 by DNT cells in a single-arm and open-label trial assessing the response to sirolimus in active SLE patients with resistance or intolerance to conventional therapeutic agents. Here, IL4 is linked to systemic lupus erythematosus.